What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free break-even services with professional advisors to help you quickly recover and avoid losses, achieving steady growth. What factors are pushing Kalpataru Projects International Limited (522287) up - Free Exclusive Investment Tips ✌️【Expert Advice】✌️ Expert market predictions with real-time global market, futures, metals, and energy data to help you stay in tune with market trends.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free break-even services with professional advisors to help you quickly recover and avoid losses, achieving steady growth. For Christy Nguyen, menopause hit just as the Covid-19 pandemic did. With both, she said, came unwanted weight gain.

“I had gained 30 pounds in about two years, and so I was sort of desperate to find something” to help with weight loss, the 56-year-old mother of two said. She’d tried WeightWatchers and the keto diet, hoping to lose weight and be able to stop taking her recently prescribed medicines for high blood pressure and cholesterol. But nothing seemed to work.

Poison centers see nearly 1,500% increase in calls related to injected weight-loss drugs as people accidentally overdose

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ AI-powered stock trend analysis with free, up-to-the-minute updates. Analyze global stock, futures, and forex data to capture market movements and make smart investment choices with expert insights. That’s how Nguyen found herself on a 15-month journey through a new class of medications like Ozempic and Wegovy. Known as GLP-1 receptor agonists, they’re exploding in popularity but can sometimes be impossible to get because of insurance hurdles and shortages. Like an increasing number of patients, Nguyen began taking a decades-old prescription drug for weight loss instead.

“People come in the door seeking treatment with a GLP-1, and then for whatever reason, they can’t get it or change their mind,” said Nguyen’s physician, Dr. Jody Dushay of Beth Israel Deaconess Medical Center.

Older weight-loss medicines have several benefits, Dushay said. They can be more affordable, even out-of-pocket; are less likely to be in shortage; come with different side effects than Wegovy and similar drugs; and are pills instead of injections.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free access to stock market forums, expert advice, and real-time data to help you stay informed and grow your investments. As overall prescriptions of weight-loss drugs have soared, those for older medicines in the category have as well – although on a more modest scale than drugs like Wegovy, according to data from Epic Research provided exclusively to 【 - Free Exclusive Investment Tips 】.

It started for Nguyen in spring 2022, when a previous doctor prescribedWegovy. But even though she qualified based on her body mass index – about 35, she said – the medicine costs more than $1,000 a month, and Nguyen’s insurance wouldn’t cover it. So her doctor prescribed its sister drug,Ozempic, which is approved for type 2 diabetes and uses the same key ingredient, semaglutide, at generally lower doses. It’s often used off-label for weight loss.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Get precise stock market predictions and free access to real-time market data for efficient decision-making and portfolio growth. Nguyen, who lives outside Boston, said she was able to find a three-month supply of Ozempic for $900 through a website that allowed her to order the drug from Canada. Over those three months, she said, she lost 10 pounds.

“It wasn’t crazy fast,” Nguyen said. “It was enough to sort of feel like ‘oh, great. I found something that works.’”

But after three months, Nguyen said, it wasn’t sustainable for her to keep paying so much out of pocket for the medicine. By that point, a new option had come on the market:Mounjaro, a drug similar to Ozempic that’s approved for type 2 diabetes. The manufacturer, Eli Lilly, offered a coupon to lower some patients’ copays, and that helped Nguyen get that medicine for about a year.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Expert analysis of global stock trends, futures data, and real-time stock market quotes to help you plan your next investment move. She lost an additional 10 pounds and thinks she could have lost even more, except the drug was starting to be in short supply in higher doses, so she was stuck on a lower dose for longer than she otherwise might have been.

Even so, Nguyen said, she’d finally found something that was working for her, something that quieted the “food noise” that had made it hard to lose weight in the past.

“I just kind of felt neutral about it for the first time,” Nguyen said. And more than that, she said, having new medicines like these was gratifying in how she felt the field of medicine was approaching weight loss.

“Suddenly, you sort of feel seen and heard for the first time,” Nguyen said, “when obesity is kind of talked about as a disease rather than as a sort of lazy lifestyle.”

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free real-time global stock trend updates to help you capture market movements and make better investment decisions. Then the Mounjaro coupon program ended, and Nguyen was left without access to the medicines yet again.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Professional investment advice with real-time updates on stock indices and futures data. Stay ahead with expert predictions and market insights. Nguyen’s doctor then tried prescribing an older medicine from the same GLP-1 class, called Saxenda. Nguyen’s insurance denied it, she recalled, “because my BMI was not in the morbidly obese category.”

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free break-even services and stock analysis to help you recover quickly from losses and increase your chances of making profitable investments. The US Centers for Disease Control and Preventiondefinesobesity as a BMI of 30 or more, and Saxenda – as well as other GLP-1 drugs – isapproved for people with a BMI of at least 30, or with a BMI of 27 and at least one weight-related condition, like high blood pressure.

【 - Free Exclusive Investment Tips 】 Exclusive: Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Real-time global stock market trend analysis to help you identify profitable opportunities and improve your investment strategies. The CDC classifies BMI of 35 to 40 as “class 2 obesity” and 40 and higher as “class 3,” or what some refer to as severe or, previously, “morbid” obesity.

“So I’m like, ‘Well, you know, if you want me to become morbidly obese, I guess I’ll come back and talk to you in about a year, because we’ll probably be there by then,’” Nguyen said. “I’m not fat enough, or something.”

In the three months after Nguyen stopped Mounjaro, from August to November, she said, she gained back about 80% of the 20 pounds she’d lost over the previous 15 months.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Expert predictions on stock market movements with real-time data, ensuring you can make quick decisions and capture market opportunities. That’s when she was referred toDushay, an endocrinologist focused on obesity and type 2 diabetes at Beth Israel and an assistant professor of medicine at Harvard Medical School. The two started brainstorming about options.

It’s a conversation Dushay says she has with many of her patients as the popularity of new drugs like Ozempic leads people to seek weight loss treatment where they might not have before, but then they encounter barriers to actually getting the medicines.

“I think there is this underlying sense of ‘I should be able to do this on my own,’ which doesn’t apply to a lot of other chronic diseases and which, I think, is a misperception for many reasons,” Dushay said.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free access to real-time stock indices, futures data, and market predictions to help you select high-return stocks and build a profitable portfolio. The boom in popularity of new drugs, she said, “I think maybe has allowed people to seek medical care for the treatment of a disease the same way you would if you had diabetes or if you had high blood pressure.”

Because of chronicshortagesof Mounjaro, Ozempic and Wegovy, insurance denials and myriad other reasons, Dushay and other doctors have been reachingfor tools they used before those drugs became available: older prescription medicines used both on- and off-label for weight loss, like phentermine, metformin and bupropion.

For Nguyen, Dushay prescribed bupropion, firstapprovedby the US Food and Drug Administration in 1985 and best known as the brand-name antidepressant Wellbutrin. It’s also approved for smoking cessation and, in 2014, wasapprovedby the FDA for weight loss in combination with another drug, naltrexone, as Contrave.

“You can try it for people in whom afternoon or evening snacking is a big problem or who have lots of craving for sweets,” Dushay said. “Similar to the way that it helps to work for smoking cessation, through cravings – I think that’s the primary mechanism through which it can help.”

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Professional stock market predictions and analysis with real-time data to guide your investment decisions and ensure steady growth. Nguyen said in November that after a week on bupropion, she felt it may finally have stopped the continuous weight gain she’d been experiencing since she lost access to Mounjaro.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free stock selection service with expert predictions and real-time market insights, providing you with the best investment strategies for long-term success. Rates of weight-loss prescriptions among adults characterized as overweight have more than doubled since 2017, according to data fromEpic Researchbased on analysis of millions of electronic health records. Just from2022 to 2023, the data shows, rates jumped 25%.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Real-time updates on global stock trends and expert market analysis to help you select profitable stocks and grow your wealth effectively. The biggest increases are for semaglutide and tirzepatide, the generic names for Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). But there have also been significant increases in prescription rates of older medicines.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Expert predictions of stock trends to help you select high-potential stocks and achieve stable growth. Real-time global market indices, futures, metals, energy, and agricultural product data to help you seize market opportunities. Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for patients with most common form of heart failure, trial finds

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Professional advisors provide accurate market predictions with real-time stock indices, exchange rates, and futures data to help you seize investment opportunities and grow your capital. The prescription rate for bupropion rose 29% between 2017 and 2023, according to Epic’s data, while the rate for phentermine, approved by the FDA in 1959, is up 34%. The analysis looked at adults characterized as overweight who had prescriptions for any medicines in a given year and the rates who were prescribed a weight-loss drug.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Precise stock selection service to help you avoid losses and quickly recover and grow. Provides real-time global market, metals, energy, and agricultural product data to assist you in making informed decisions. The numbers are bigger for the newer medicines: Semaglutide’s prescription rate nearly doubled in the past year alone, while tirzepatide’s rose 141%. Semaglutide was approved as Ozempic for type 2 diabetes in 2017 and cleared for chronic weight management as Wegovy in 2021. Tirzepatide, as Mounjaro for type 2 diabetes, was cleared in May 2022 and last month for weight loss asZepbound.

“Not everybody has insurance coverage for the new medications,” said Dr. Louis Aronne, director ofthe Comprehensive Weight Control Centerat Weill Cornell Medicine who uses older medicines, as well as newer ones, extensively in his practice. “So they’re doing what they can to lose weight.”

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free stock market analysis and real-time data to help you select the best investment portfolio and achieve stable returns. The older medicines can be very effective, he said, but as with any class of medication,it’s a matter of finding the right one for each person. Phentermine, for example, can increase heart rate and blood pressure, so he said he wouldn’t reach for that drug for someone with cardiovascular disease.

Phentermine was part of the notoriousfen-phencombination that led to serious heart valve problems in some patients; the other medicine in the combination, fenfluramine, waspulledfrom the market in 1997. The FDA didn’t request removal of phentermine.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Expert predictions with real-time stock trends, futures prices, and exchange rate changes to help you select stocks accurately and increase investment returns. The medicine was also approved as part of a combination with another drug, topiramate, as the weight-loss drugQsymiain 2012.

Clinical trials of Qsymia and Contrave didn’t yield as much weight loss as the GLP-1 class, and the medicines never became commercial successes.

Drug in Ozempic may enable patients with newly diagnosed type 1 diabetes to stave off insulin use, small study suggests

For some people, the newer medicines are less appealing precisely because they are new. Sixty-two-year-old Henry Benson said he’d lost about 70 pounds over four years through alifestyle programwith Dushay and was hoping to lose 20 more. He and Dushay discussed Wegovy and other similar medicines, and he decided they weren’t for him.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free real-time stock data analysis to help you capture global market trends and steadily grow your capital. The potential side effects associated with GLP-1s sounded “particularly unpleasant,” he said; they can include nausea, vomiting and constipation, particularly as patients first start the medicines.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Expert predictions of stock trends with real-time stock indices, metals, energy, and agricultural product data to help you make efficient investment decisions. Additionally, he said, “the drug is relatively new, so we don’t really know what the long-term side effects are. … I just I looked at all of that and I said, ‘You know what, I just don’t think that this is right for me.’”

He and Dushay settled on metformin, a generic drug approved in 1994 for type 2 diabetes. He’s lost about five more pounds, and his goal is to stop taking the medicine after losing about 15 additional pounds and then to maintain his weight loss without medication. He noted that he’s already been able to stop other medicines, like statins, because his cholesterol levels fell with changes he made in the kinds of foods he was eating.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Precise stock market trend predictions with free real-time quotes for India stocks, US stocks, and European stocks to help you seize the best investment timing. And although physicians are happy to have new tools like GLP-1s, their increased use can come with downsides, saidDr. Zhaoping Li, a professor of medicine and chief of the Division of Clinical Nutrition at the University of California, Los Angeles.

“People are losing weight, all right, but they’re also losing a lot of muscle,” which can be particularly worrisome for geriatric patients, Li said. “Another major issue is, people are eating so little, they start to have malnutrition and vitamin deficiencies. So it’s not a free ride for everyone to a better place.”

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Professional investment advisors provide real-time market data to help you analyze stock trends and select high-potential stocks, increasing capital growth. Those risks, doctors said, must be balanced with dramatic benefits from the new medicines; Dushay and Aronne both cite trialresultsfrom this year showing that Wegovy can reduce the risk of heart attacks, strokes or heart-related death in people with cardiovascular disease by 20%, in addition to weight loss.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free stock selection service with precise predictions of high-potential stocks to help you stay ahead in the market. And with Zepbound newly available from Eli Lilly, patients like Nguyen are hoping for better luck getting access to it. Dushay said that about75% of her requests for insurance coverage of the drug, which waspricedat a discount to Wegovy but still at more than $1,000 per month, have been getting denied. Wegovy, Dushay said, has improved coverage after being on the market for longer, but it’s inshortage,particularly in lower doses.

Like it did for Mounjaro, Lilly is offering acouponto lower some patients’ out-of-pocket costs. Nguyen said her insurance denied coverage, but the savings card allows her to pay $550 a month. She plans to use that as she starts on lower doses of Zepbound and, when she’s reached a higher dose, potentially switch to Wegovy, which is covered.

What factors are pushing Kalpataru Projects International Limited (522287) up ✌️【Expert Advice】✌️ Free real-time global stock trend updates to help you capture market movements and make better investment decisions.